Unveiling Forgetfulness: A Deep Dive into Academic Literature Validating Unintentional Non-Adherence in the MMAS-8

1. Study: Validation of MMAS-8 in Asthma Patients (2017)
• Source: Criterion validity of 8-item Morisky Medication Adherence Scale in patients with asthma, PLOS One
• Methods Integrated:
• Pharmacy Refill Records: Data on asthma medication dispensing were collected from community pharmacy claims to validate self-reported adherence.
• Qualitative Interviews: Introductory interviews gathered patient-reported data on asthma treatment, exacerbations, and demographic characteristics to contextualize MMAS-8 responses.
• Clinical Outcomes (Asthma Control Test, ACT): The study assessed criterion validity by correlating MMAS-8 scores with asthma control (ACT) and quality of life (Saint George Respiratory Questionnaire, SGRQ).
• Findings:
• The study included 208 asthma patients (mean age 56, 59% female). MMAS-8 responses, including items 1, 4, and 8 (forgetfulness-related), were compared with pharmacy claims data and clinical outcomes.
• Asthma was uncontrolled in 37% of patients, and 22% had exacerbations, suggesting non-adherence. MMAS-8 showed moderate criterion validity, but forgetfulness (e.g., item 1: “Do you sometimes forget to take your medication?”) was not strongly correlated with pharmacy refill gaps, indicating possible intentional non-adherence or recall bias.
• Qualitative interviews helped clarify that some patients reported forgetfulness due to complex regimens or situational factors (e.g., travel, item 4).
• Relevance to Forgetfulness: The integration of pharmacy records and interviews helped validate whether reported forgetfulness aligned with objective non-adherence patterns, though discrepancies suggested some patients may misreport intentional non-adherence as forgetfulness.
• Limitations: Pharmacy claims don’t confirm medication ingestion, and interviews may be subject to social desirability bias.
2. Study: MMAS-8 in Gout Patients (2016)
• Source: Utility of the Morisky Medication Adherence Scale in gout: a prospective study, Patient Preference and Adherence
• Methods Integrated:
• Pharmacy Refill Records: Medication Possession Ratio (MPR) was used to measure adherence to urate-lowering therapy (ULT) and compared with MMAS-8 scores.
• Clinical Outcomes: Serum urate levels and remission status were correlated with MMAS-8 responses to assess construct validity.
• Qualitative Patient-Reported Outcomes: The Gout Impact Scale (GIS) and EuroQoL-5 dimension (EQ5D) collected patient perspectives on adherence barriers, including forgetfulness.
• Findings:
• The study involved a multiethnic Asian cohort on ULT. MMAS-8 had good internal consistency (Cronbach’s alpha = 0.73) and test-retest reliability (ICC = 0.702). However, there was no significant correlation between MMAS-8 scores and MPR (r = 0.069, p = 0.521), suggesting that self-reported forgetfulness (items 1, 4, 8) did not always align with refill data.
• Patients reporting forgetfulness often cited concerns about side effects or underlying anxiety/depression, identified through GIS and EQ5D, indicating that forgetfulness may mask intentional non-adherence.
• The study identified patients with forgetfulness-related non-adherence (e.g., item 4: travel-related) who benefited from targeted education, suggesting intervention trials could validate these barriers.
• Relevance to Forgetfulness: The combination of MPR and patient-reported outcomes helped distinguish genuine forgetfulness from other barriers, though weak correlation with MPR highlighted limitations in self-reports.
• Limitations: MPR assumes medication is taken as prescribed, which may not reflect actual behavior. The study did not use electronic monitoring or cognitive assessments.
3. Study: MMAS-8 in Psychiatric Outpatients (2014)
• Source: Psychometric properties of the eight-item Morisky Medication Adherence Scale in a psychiatric outpatient setting, International Journal of Clinical and Health Psychology
• Methods Integrated:
• Qualitative Interviews: Conducted with 967 psychiatric outpatients to collect MMAS-8 responses and socio-demographic/clinical data.
• Cognitive Assessments (Indirect): The study correlated MMAS-8 scores with psychological measures (e.g., Drug Attitude Inventory, Multidimensional Health Locus of Control, Hong Psychological Reactance Scale) to assess cognitive and attitudinal factors influencing forgetfulness.
• Clinical Outcomes: MMAS-8 was used to differentiate adherence levels across mental disorder diagnoses (e.g., schizophrenia, depression), indirectly validating forgetfulness through clinical patterns.
• Findings:
• The Spanish version of MMAS-8 showed adequate construct validity (one-factor solution) and significant correlations with psychological measures. Item 8 (“How often do you have difficulty remembering to take all your medications?”) had the highest factor loading (r = 0.74), emphasizing forgetfulness as a key barrier.
• Patients with higher psychological reactance or belief that health depends on chance reported more forgetfulness, suggesting cognitive torpedoing as a cognitive issue. Qualitative interviews provided context for these responses.
• No direct cognitive tests were used, but psychological scales indirectly assessed cognitive factors like memory or attention.
• Relevance to Forgetfulness: The study validated forgetfulness (items 1, 4, 8) by linking MMAS-8 responses to psychological factors, suggesting that cognitive issues contribute to unintentional non-adherence in psychiatric patients.
• Limitations: Lack of objective measures like electronic monitoring or pharmacy records limited direct validation of forgetfulness. The study relied heavily on self-reports and psychological correlations.
4. Study: MMAS-8 in Hypertensive Seniors (2009)
• Source: New medication adherence scale versus pharmacy fill rates in seniors with hypertension, American Journal of Managed Care
• Methods Integrated:
• Pharmacy Refill Records: Pharmacy fill rates were compared with MMAS-8 scores to assess adherence in hypertensive seniors.
• Clinical Outcomes: Blood pressure control was used as a proxy for adherence, correlating with MMAS-8 responses.
• Findings:
• The study found that MMAS-8 scores, including forgetfulness-related items (1, 4, 8), had moderate concordance with pharmacy fill rates (sensitivity and’)
• specificity values not fully reported). Patients reporting forgetfulness (e.g., item 1) often had lower fill rates, supporting the validity of self-reported forgetfulness, though some discrepancies suggested intentional non-adherence.
• Blood pressure control was significantly associated with higher MMAS-8 scores (p < 0.05), reinforcing the link between reported adherence and clinical outcomes.
• Relevance to Forgetfulness: Pharmacy refill data provided an objective measure to validate self-reported forgetfulness, while clinical outcomes offered indirect evidence of adherence behaviors.
• Limitations: No electronic monitoring or cognitive assessments were included, and pharmacy data cannot confirm actual medication ingestion.
5. Study: Technologies for Medication Adherence Monitoring (Narrative Review, 2020)
• Source: Technologies for Medication Adherence Monitoring and Technology Assessment Criteria, PMC
• Methods Integrated:
• Electronic Monitoring Devices: Reviewed studies using Medication Event Monitoring Systems (MEMS) and video-based directly observed therapy (VDOT) to track adherence, often compared with self-reports like MMAS-8.
• Intervention Trials: Discussed trials testing reminder systems (e.g., smart pill bottles, mobile apps) to address forgetfulness, measuring changes in adherence.
• Qualitative Studies: Included qualitative analyses of patient experiences with adherence technologies, exploring reasons for forgetfulness.
• Findings:
• Electronic monitoring (e.g., MEMS) showed that self-reported forgetfulness on MMAS-8 (items 1, 4, 8) often overestimated adherence compared to device data, with discrepancies in up to 30% of cases in some studies.
• Intervention trials with reminders improved adherence in patients reporting forgetfulness, supporting the validity of these claims. For example, a study cited in the review found that smart pill bottles reduced missed doses by 20% in patients with high forgetfulness scores on MMAS-8.
• Qualitative data revealed that forgetfulness was often linked to complex regimens or lack of routines, validating situational barriers (e.g., item 4: travel-related forgetfulness).
• Relevance to Forgetfulness: The integration of electronic monitoring and intervention trials provided robust evidence that forgetfulness is a significant barrier, particularly when confirmed by reduced missed doses after reminder interventions.
• Limitations: Electronic monitoring is a proxy measure (e.g., bottle openings don’t confirm ingestion), and qualitative data may be biased. The review noted high costs of MEMS as a barrier to widespread use.
Key Insights from Integrated Approaches
• Complementary Strengths: Combining objective measures (e.g., pharmacy refills, electronic monitoring) with subjective methods (e.g., MMAS-8, interviews) helps validate forgetfulness by cross-referencing self-reports with behavioral data. For example, the asthma study () used pharmacy data and interviews to confirm that forgetfulness was a common but sometimes overstated reason for non-adherence.
• Intervention Trials as Validation: Studies testing reminder systems (e.g.,) provide strong evidence for forgetfulness when adherence improves post-intervention, as seen in trials where smart pill bottles reduced missed doses for patients reporting forgetfulness on MMAS-8.
• Cognitive and Psychological Context: Psychiatric studies () highlight that forgetfulness may be influenced by cognitive factors (e.g., memory issues) or psychological reactance, validated through correlations with psychological scales rather than direct cognitive tests.
• Limitations:
• Objective measures like MEMS or pharmacy refills don’t confirm ingestion, only access to medication.
• Self-reports, including MMAS-8, are prone to social desirability bias, where patients may over-report forgetfulness to mask intentional non-adherence ().
• Few studies integrate all methods (e.g., cognitive assessments are rarely combined with electronic monitoring), limiting comprehensive validation.